Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032201 · ClinicalTrials.gov registry record
Cell Lines From High-Risk Breast Tissue
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 43
- Enrollment target
NCT00032201 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants.
The verdict
NCT00032201 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
Background: * Many risk factors for breast cancer have been identified, including family history, endocrine background, changes in breast tissue, cancer in one breast, radiation exposure, obesity and others. There is a spectrum of tissue changes seen in cancerous and pre-cancerous breast tissue. * A cell line is a collection of cells that are grown in the laboratory from an original tissue specimen. Cell lines developed from high-risk breast tissue allow researchers to perform metabolic and molecular studies of breast cells over time. Objective: To establish a repository (facility in which tissue samples can be preserved and stored for many years) of cell lines from high-risk breast tissue to allow researchers to learn more about changes in breast cells that may cause them to develop into breast cancer. Eligibility: Women between 20 and 80 years of age who: * Have an increased risk of breast cancer because they are members of a high-risk breast or ovarian cancer family. * Have had breast cancer in one or both breasts. * Have had radiation for lymphoma before the age of 30. * Have a mutation in a breast cancer susceptibility gene, but whose family history is not known. * Are not at increased risk of breast cancer. Design: * A small piece of breast tissue will be obtained from about 10 women without an identified risk of breast cancer and up to 100 women at high risk of developing breast cancer. * Cell lines will be developed from each high-risk category. * The cell lines and tissues will be used to establish a repository of high-risk breast cell lines and breast tissues that can be used to study how the cells develop into breast cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2002-03-06 |
| Est. Completion | 2014-12-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032201
The ClinicalTrials.gov registry entry for NCT00032201 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00032201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00032201 about?
NCT00032201 is a clinical study titled "Cell Lines From High-Risk Breast Tissue". Background: * Many risk factors for breast cancer have been identified, including family history, endocrine background, changes in breast tissue, cancer in one breast, radiation exposure, obesity and others. There is a spectrum of tissue changes seen in cancerous and pre-cancerous breast tissue. * ...
What is the current status of trial NCT00032201?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2002-03-06. Estimated completion is 2014-12-03.
Who is sponsoring clinical trial NCT00032201?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.